Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath of hope: inhaled mRNA vaccine targets lung tumors

NCT ID NCT06928922

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an inhaled mRNA vaccine called BMD006 in 83 people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-associated antigens. The study will check safety, tolerability, and early signs of effectiveness, and may also explore combining the vaccine with other cancer drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BMD006 (inhaled mRNA dry powder vaccine)
What this could lead to
If it works, this could offer a new treatment option for people with advanced lung cancer or lung metastases who have run out of standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 83 participants, so safety and effectiveness are not yet proven. The vaccine may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG CANCER LUNG METASTASIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.